CCANED-CIPHER v1.0 – AI blood RNA for cancer detection & response
Research type
Research Study
Full title
Common Cancer Early Detection (CCANED) & Cancer Immuno-Profiling of Hematologic and Extracellular RNA (CIPHER): a UK, observational blood-based study for early detection and treatment-response monitoring.
IRAS ID
350891
Contact name
Denise Williams
Contact email
Sponsor organisation
Dysplasia Diagnostics Limited
Clinicaltrials.gov Identifier
NCT06717295, https://clinicaltrials.gov/
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
We are developing a simple blood test that, with advanced computer analysis, could help detect cancer earlier and track how well treatments are working. In this UK observational study, adults will give small blood samples. We will isolate blood component and measure RNA molecules. Using machine-learning, we will look for patterns that distinguish people with cancer from those without, and monitor how these patterns change during treatment.
The study has two phases:
Phase 1 (CCANED): Single-visit sampling from people with common cancers and from cancer-free controls to assess diagnostic accuracy.Phase 2 (CIPHER): Repeated samples from people starting cancer treatment (baseline, ~6 weeks, ~6 months) to see whether blood markers reflect response or early relapse.
Participation involves a standard blood draw and short questionnaires. No clinical decisions are based on research results and no individual results are returned. All data are pseudonymised, stored securely, and handled under UK data protection law. The long-term aim is a scalable, minimally invasive test to support better cancer outcomes.REC name
London - Riverside Research Ethics Committee
REC reference
25/PR/1420
Date of REC Opinion
9 Dec 2025
REC opinion
Further Information Favourable Opinion